118 related articles for article (PubMed ID: 28664723)
1. Delivery and Release of Small-Molecule Probes in Mitochondria Using Traceless Linkers.
Lei EK; Kelley SO
J Am Chem Soc; 2017 Jul; 139(28):9455-9458. PubMed ID: 28664723
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel heat shock protein (Hsp90) inhibitors based on luminespib with potent antitumor activity.
Jung J; Kwon J; Hong S; Moon AN; Jeong J; Kwon S; Kim JA; Lee M; Lee H; Lee JH; Lee J
Bioorg Med Chem Lett; 2020 Jun; 30(12):127165. PubMed ID: 32305165
[TBL] [Abstract][Full Text] [Related]
3. Optimized HSP90 mediated fluorescent probes for cancer-specific bioimaging.
Zhu S; Li Y; Huang Y; Zhang M; Gu X; He Y; Liu H; Ma M; Lu W
J Mater Chem B; 2020 Mar; 8(9):1878-1896. PubMed ID: 32037409
[TBL] [Abstract][Full Text] [Related]
4. Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.
Wang Y; Koay YC; McAlpine SR
Chemistry; 2017 Feb; 23(9):2010-2013. PubMed ID: 27862436
[TBL] [Abstract][Full Text] [Related]
5. Discerning the Chemistry in Individual Organelles with Small-Molecule Fluorescent Probes.
Xu W; Zeng Z; Jiang JH; Chang YT; Yuan L
Angew Chem Int Ed Engl; 2016 Oct; 55(44):13658-13699. PubMed ID: 27571316
[TBL] [Abstract][Full Text] [Related]
6. Evolution of kinase polypharmacology across HSP90 drug discovery.
Antolin AA; Clarke PA; Collins I; Workman P; Al-Lazikani B
Cell Chem Biol; 2021 Oct; 28(10):1433-1445.e3. PubMed ID: 34077750
[TBL] [Abstract][Full Text] [Related]
7. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
8. How Selective are Hsp90 Inhibitors for Cancer Cells over Normal Cells?
Wang Y; Koay YC; McAlpine SR
ChemMedChem; 2017 Mar; 12(5):353-357. PubMed ID: 28139075
[TBL] [Abstract][Full Text] [Related]
9. Sulfoxythiocarbamate S-4 inhibits HSP90 in human cutaneous squamous cell carcinoma cells.
Zhang Y; VanHecke GC; Ahn YH; Proby CM; Dinkova-Kostova AT
Eur J Pharmacol; 2020 Dec; 889():173609. PubMed ID: 33031796
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 3,5-disubstituted-4-alkynylisoxozales as a novel class of HSP90 inhibitors.
Sun J; Lin C; Qin X; Dong X; Tu Z; Tang F; Chen C; Zhang J
Bioorg Med Chem Lett; 2015 Aug; 25(16):3129-34. PubMed ID: 26112442
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
[TBL] [Abstract][Full Text] [Related]
12. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
13. Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.
Cheng W; Ainiwaer A; Xiao L; Cao Q; Wu G; Yang Y; Mao R; Bao Y
Mol Med Rep; 2015 Aug; 12(2):2451-6. PubMed ID: 25955495
[TBL] [Abstract][Full Text] [Related]
14. Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.
Yang Q; Puhm F; Freissmuth M; Nanoff C
Cancer Chemother Pharmacol; 2017 Oct; 80(4):673-684. PubMed ID: 28779264
[TBL] [Abstract][Full Text] [Related]
15. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
[TBL] [Abstract][Full Text] [Related]
16. New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting.
Rondanin R; Lettini G; Oliva P; Baruchello R; Costantini C; Trapella C; Simoni D; Bernardi T; Sisinni L; Pietrafesa M; Ponterini G; Costi MP; Vignudelli T; Luciani R; Matassa DS; Esposito F; Landriscina M
Bioorg Med Chem Lett; 2018 Jul; 28(13):2289-2293. PubMed ID: 29807796
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.
Huyan T; Li Q; Dong DD; Yang H; Zhang J; Huang QS; Yin DC; Shang P
Immunopharmacol Immunotoxicol; 2016; 38(2):77-86. PubMed ID: 26642940
[TBL] [Abstract][Full Text] [Related]
20. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]